Cancer linked mutations in brain immune cells tied to Alzheimer’s disease

Wednesday 22 April 2026 - 08:20

By: Dakir Madiha

Cancer linked mutations in brain immune cells tied to Alzheimer’s disease

Researchers have identified cancer associated genetic mutations in brain immune cells that may play a direct role in the development of Alzheimer’s disease, offering a new explanation for how the condition progresses and opening potential paths for diagnosis and treatment. The findings show that microglia, the brain’s resident immune cells, accumulate mutations commonly seen in blood cancers, reshaping current understanding of neurodegeneration.

The study analyzed 149 genes linked to cancer across brain tissue samples from 190 individuals diagnosed with Alzheimer’s disease and 121 healthy donors. The results revealed a higher number of DNA alterations in Alzheimer’s brains, with recurring mutations concentrated in five key cancer driver genes. These mutations are typically associated with diseases such as leukemia and lymphoma, suggesting a shared biological mechanism between cancer and neurodegeneration.

Further investigation found that the same mutations detected in brain microglia were also present in the blood of Alzheimer’s patients. This indicates that mutated immune cells originating in the bloodstream may migrate into the brain. Scientists believe that as the blood brain barrier weakens with age or injury, these altered cells cross into the brain and adopt microglia like functions. Once inside, they encounter protein aggregates such as amyloid and tau, which create conditions that favor their expansion while amplifying inflammation.

This inflammatory environment appears to accelerate neuronal damage. Unlike healthy microglia, mutated cells generate a more aggressive immune response, contributing to the death of surrounding neurons. The mechanism offers a new explanation for the chronic inflammation observed in Alzheimer’s and links it directly to genetic mutations previously thought to be limited to cancer biology.

The discovery also has clinical implications. Detecting these mutations in blood samples could enable earlier identification of individuals at risk of developing Alzheimer’s disease. In addition, the overlap with cancer pathways raises the possibility of repurposing existing oncology drugs to target these mutated immune cells. Follow up research has shown that these cancer related mutations increase Alzheimer’s risk independently of established genetic factors such as APOE4, reinforcing their potential importance in disease progression.